MORE INFORMATION

Useful clinical study websites:

This document provides a summary of the main results of the study. It includes information about the side effects that happened in the study and the results of the questions the researchers wanted to answer.

A full report may be available to read at one of the following clinical trial registers:

www.clinicaltrials.gov
Use the study number NCT02605993 to search for more information on this website.

www.clinicaltrialsregister.eu
Use the study number 2015-002674-20 to search for more information on this website.

Further studies:

Several studies investigating ravulizumab for the treatment of PNH are either currently running or completed. Please follow the links below to find out more information.

- PNH Registry
- ALXN1210-PNH-103: Dose-escalation study of ravulizumab in adults with PNH
- ALXN1210-PNH-301: Ravulizumab versus eculizumab in adults with PNH
- ALXN1210-PNH-302: Adults with PNH currently treated with eculizumab
- ALXN1210-PNH-303: Ravulizumab administered subcutaneously versus intravenously
- ALXN1210-PNH-304: Children and adolescents with PNH

Protocol, ALXN1210-PNH-201

SPONSOR CONTACT INFORMATION:
Europe, 2015-002674-20 1-888-765-4747

Note: Delete text as copyright, for example: "Certara USA, Inc. 2020. All rights reserved".